Company Focus

Almost 425 Million people suffer from obstructive sleep apnea (OSA) syndrome which significantly affects their quality of life and OSA is strongly associated with cardiovascular and metabolic comorbidities; it is highly prevalent in populations with diabetes, hypertension, heart disease, and stroke.

Recommended therapies can relieve symptoms and reduce some of the associated of the associated sequelae.

The gold standard treatment of OSA is continuous positive airway pressure (CPAP), over 85% of treated patients are with CPAP.

CPAP is cumbersome and uncomfortable, 15% of patients refuse CPAP and a recent study shows that 50% of patients treated with CPAP will drop out during the first 3 years of treatment.

New approaches to treat OSA are required, after non-adherence to CPAP or to treat specific populations.

Our Technology

The solution is a new noninvasive device that detects and treat sleep apnea syndrome using a Kinesthetic stimulation.

The universities of Rennes and Grenoble have successfully tested this new therapeutic approach based on non-invasive kinesthetic stimulation. The first clinical trials have demonstrated the relevance of this technique.

Pasithea will aim to bring the technology to the medical device market.

Company Status

The technology is patented (8 Patents), has been the subject of a PhD thesis by an engineer and several clinical peer-reviewed publications have been produced.

The next steps will be the miniaturization of the device, its compliance with medical device requirements and its intended use, obtained from clinical studies.

News from Pasithea


PASITHEA, an NLC venture, sets out to help people with sleep apnea by developing a new medical device. In our world today,  approximately 425 million

Read More »